Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 10:10 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1753–1776 of 9,381 matching trials from the live ClinicalTrials.gov search.
Conditions
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Lineage Acute Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia of Ambiguous Lineage
Interventions
revumenib, cobicistat
Drug
Lead sponsor
Syndax Pharmaceuticals
Industry
Eligibility
30 Days and older
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
22
States / cities
Duarte, California • Los Angeles, California • Palo Alto, California + 17 more
Conditions
Herpes Simplex Infections
Interventions
Not listed
Lead sponsor
Hologic, Inc.
Industry
Eligibility
Not listed
Enrollment
839 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
22
States / cities
Birmingham, Alabama • Phoenix, Arizona • Canoga Park, California + 19 more
Conditions
Ventral Hernia, Incisional Hernia
Interventions
Resorbable Mesh
Device
Lead sponsor
C. R. Bard
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
16
States / cities
San Diego, California • Celebration, Florida • Evanston, Illinois + 13 more
Conditions
Chronic Anal Fissures
Interventions
VEN 307, Placebo
Drug
Lead sponsor
Ventrus Biosciences, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
434 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
103
States / cities
Anniston, Alabama • Mobile, Alabama • Montgomery, Alabama + 85 more
Completed Phase 1Phase 2 Interventional Results available

Phase 1/2 Study in Boys With Duchenne Muscular Dystrophy

NCT02439216
Conditions
Muscular Dystrophy, Duchenne
Interventions
Edasalonexent, Placebo
Drug
Lead sponsor
Catabasis Pharmaceuticals
Industry
Eligibility
4 Years to 7 Years · Male only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
5
States / cities
Los Angeles, California • Gainesville, Florida • Orlando, Florida + 2 more
Conditions
Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasm Metastasis
Interventions
Sofetabart Mipitecan, Paclitaxel, Topotecan, Gemcitabine, Pegylated liposomal doxorubicin (PLD), MIRV, Bevacizumab, Carboplatin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
85
States / cities
Birmingham, Alabama • Phoenix, Arizona • Burbank, California + 67 more
Conditions
Stereotypical Prolonged Seizures
Interventions
Staccato alprazolam, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
12 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
66
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 50 more
Conditions
Cerebrovascular Accident, Hypertension
Interventions
aspirin, clopidogrel, Target of Blood Pressure, placebo
Drug · Other
Lead sponsor
University of British Columbia
Other
Eligibility
30 Years and older
Enrollment
3,020 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
39
States / cities
Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 32 more
Conditions
Hepatocellular Carcinoma
Interventions
TheraBionic Device, Placebo Device, Quality of Life Assessment
Device
Lead sponsor
THERABIONIC INC.
Other
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
7
States / cities
Tampa, Florida • Chicago, Illinois • Winston-Salem, North Carolina + 4 more
Conditions
Major Depressive Disorder
Interventions
AZD2066, Placebo, Duloxetine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
13
States / cities
Garden Grove, California • San Diego, California • Jacksonville, Florida + 10 more
Completed No phase listed Observational Accepts healthy volunteers

Vietnamese Women's Health Project III

NCT01704235
Conditions
Cervical Cancer
Interventions
Demographic Form and Semi-Structured Interview Guide
Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
21 Years to 65 Years · Female only
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Mitral Valve Insufficiency
Interventions
Half Moon TMVr System
Device
Lead sponsor
Half Moon Medical
Industry
Eligibility
21 Years to 95 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
5
States / cities
New York, New York • The Bronx, New York • Cleveland, Ohio + 2 more
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, HER2 Negative Breast Adenocarcinoma, Hormone Receptor Positive Breast Adenocarcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Unilateral Breast Carcinoma
Interventions
Abemaciclib, Niraparib Tosylate Monohydrate
Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Migraine, Migraine Disorders
Interventions
sumatriptan succinate/naproxen sodium
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
35
States / cities
Chandler, Arizona • Irvine, California • Redondo Beach, California + 30 more
Conditions
Multiple Myeloma
Interventions
Arlocabtagene Autoleucel
Biological
Lead sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
41
States / cities
Birmingham, Alabama • Gilbert, Arizona • Little Rock, Arkansas + 33 more
Conditions
Gaucher Disease, Cerebroside Lipidosis Syndrome, Glucocerebrosidase Deficiency Disease, Glucosylceramide Beta-Glucosidase Deficiency Disease
Interventions
Not listed
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
Not listed
Enrollment
12,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2034
U.S. locations
91
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 68 more
Conditions
Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell, Follicular Lymphoma
Interventions
LY4584180, Rituximab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
21
States / cities
Scottsdale, Arizona • Duarte, California • Los Angeles, California + 16 more
Conditions
Gastroparesis, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
Placebo, 10mg TZP-102, 20mg TZP-102
Drug
Lead sponsor
Tranzyme, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
31
States / cities
Huntsville, Alabama • Tucson, Arizona • Jonesboro, Arkansas + 27 more
Conditions
Advanced Cancer
Interventions
Nivolumab, Daratumumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
5
States / cities
Long Beach, California • Aurora, Colorado • Tampa, Florida + 2 more
Terminated Not applicable Interventional Results available

STIP: Statin Trial for Influenza Patients

NCT00970606
Conditions
Acute Respiratory Distress Syndrome, Influenza, H1N1 Influenza
Interventions
Rosuvastatin (crestor), Placebo
Drug
Lead sponsor
Gordon Bernard
Other
Eligibility
13 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
21
States / cities
Little Rock, Alaska • Phoenix, Arizona • Stanford, California + 17 more
Conditions
Prostatic Neoplasms
Interventions
Apalutamide, Placebo
Drug
Lead sponsor
Aragon Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2029
U.S. locations
122
States / cities
Birmingham, Alabama • Anchorage, Alaska • Chandler, Arizona + 119 more
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial

NCT01222247
Conditions
Pregnancy, Respiratory Distress Syndrome, Pregnancy Outcomes, Preterm Birth
Interventions
Betamethasone, Placebo
Drug
Lead sponsor
The George Washington University Biostatistics Center
Other
Eligibility
Female only
Enrollment
2,831 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2022
U.S. locations
17
States / cities
Birmingham, Alabama • Stanford, California • Denver, Colorado + 14 more
Conditions
Atopic Dermatitis
Interventions
AK002, Placebo
Drug · Other
Lead sponsor
Allakos Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
40
States / cities
Birmingham, Alabama • Cullman, Alabama • Gilbert, Arizona + 33 more
Conditions
Advanced or Metastatic Merkel Cell Carcinoma, Advanced or Metastatic Cutaneous Squamous Cell Carcinoma, Advanced or Metastatic Melanoma, Advanced or Metastatic Head and Neck Squamous Cell Carcinoma, Advanced or Metastatic Solid Tumors
Interventions
Cavrotolimod, Pembrolizumab, Cemiplimab
Drug · Biological
Lead sponsor
Exicure, Inc.
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
26
States / cities
Tucson, Arizona • Orange, California • San Francisco, California + 21 more